Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GT BIOPHARMA INC (GTBP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.54-6.20%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GTBP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Initiate phase 1a/1b clinical trial for GTB-5550 | It plans to start a phase 1a/1b trial for GTB-5550. | Improving | trial not started or delayed beyond 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q2. The company entered a clinical trial agreement to initiate phase 1a/1b trials for GTB-5550. No revenue or operating income impact is yet reported; the priority is in early stages with limited financial delivery so far. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not an established earnings compounder. The multi-year view is in a watch state, with low confidence, volatile management signals, and no evidence yet that recent priorities have improved financial performance.
The evidence does not include a valuation measure or a clear account of market expectations, so whether GTBP is cheap or expensive versus peers cannot be assessed. Its loss-making status and recent equity issuance are known concerns, while the sector backdrop has improved.
Near term, the company faces elevated risk of another earnings miss after a run of misses. It has an agreement to begin phase 1a/1b trials for GTB-5550 and an extension to regain Nasdaq compliance by November 16, 2026, but neither priority has yet shown financial improvement.
The multi-year thesis hinges on progress in the GTB-5550 trial and whether the company regains Nasdaq compliance. Near term, weaker employment data could add pressure to cyclical and healthcare names, while continued strength or weakness from sector bellwethers such as VRTX, REGN, and MRNA could shift the sector backdrop.
Over the next 1 to 3 years, GTBP remains a high-risk, early-stage thesis with limited evidence of financial delivery and important clinical and listing milestones ahead. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce losses and improve cash flow | A supporting condition in GT BIOPHARMA INC's published investment case. The stated target is reduce net loss and improve cash flow over next 4 quarters. | Broken | losses worsen or cash flow remains negative | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Regain Nasdaq compliance by November 16, 2026 | GT Biopharma aims to regain Nasdaq compliance by November 2026. | Improving | failure to regain Nasdaq compliance by November 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q2. The company was granted a 180-day extension until November 16, 2026 to regain compliance with Nasdaq listing rules. There is no financial improvement evidence yet; the priority is newly stated and the trajectory is pending. Delivery assessment Oct 31, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.27 → $-8.00 · observed estimates
$0.07B → $0.07B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-25 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-26 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-27 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-28 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-29 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-07-30 | $-0.27 | $0 | 1 / 1 |
| 2026-07-31 | $-0.27 | $0 | 1 / 1 |
| 2026-08-01 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-02 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-03 | $-0.27 | $0 | 1 / 1 |
| 2026-08-04 | $-0.27 | $0 | 1 / 1 |
| 2026-08-05 | $-0.27 | $0 | 1 / 1 |
| 2026-08-06 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-07 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-08 | $-0.27 | $0 | 1 / 1 |
| 2026-08-09 | $-0.27 | $0 | 1 / 1 |
| 2026-08-10 | $-0.27 | $0 | 1 / 1 |
| 2026-08-12 | $-0.27 | $0 | 1 / 1 |
| 2026-08-13 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-14 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-15 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-16 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-17 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-18 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-19 | $-0.27 | $67,700,000 | 1 / 1 |
| 2026-08-20 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-21 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-22 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-23 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-24 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-25 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-26 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-27 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-28 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-29 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-30 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-08-31 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-01 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-02 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-03 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-04 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-05 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-06 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-07 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-08 | $-0.32 | $67,700,000 | 1 / 1 |
| 2026-09-09 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-10 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-11 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-12 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-13 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-14 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-15 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-16 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-17 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-18 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-19 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-20 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-21 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-22 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-23 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-24 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-25 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-26 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-27 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-28 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-29 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-09-30 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-01 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-02 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-03 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-04 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-05 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-06 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-07 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-08 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-09 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-10 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-11 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-12 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-13 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-14 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-15 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-16 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-17 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-18 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-19 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-20 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-21 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-22 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-23 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-24 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-25 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-26 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-27 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-28 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-29 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-30 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-10-31 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-11-01 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-11-02 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-11-03 | $-8.00 | $67,700,000 | 1 / 1 |
| 2026-11-04 | $-8.00 | $67,700,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.